Pfizer Inc. $PFE Shares Sold by Independent Solutions Wealth Management LLC

Independent Solutions Wealth Management LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 13.2% during the second quarter, Holdings Channel reports. The fund owned 16,872 shares of the biopharmaceutical company’s stock after selling 2,566 shares during the quarter. Independent Solutions Wealth Management LLC’s holdings in Pfizer were worth $415,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PFE. GKV Capital Management Co. Inc. acquired a new stake in Pfizer during the first quarter valued at $27,000. Bayforest Capital Ltd acquired a new position in Pfizer in the first quarter worth approximately $28,000. North Capital Inc. acquired a new stake in Pfizer in the first quarter valued at approximately $28,000. WPG Advisers LLC acquired a new position in shares of Pfizer during the 1st quarter worth $35,000. Finally, Horizon Financial Services LLC bought a new position in shares of Pfizer in the 1st quarter valued at approximately $35,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE stock opened at $26.45 on Tuesday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The firm’s 50 day moving average is $24.72 and its 200-day moving average is $24.12. The firm has a market capitalization of $150.38 billion, a price-to-earnings ratio of 14.07, a PEG ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the firm earned $0.60 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PFE has been the topic of several research reports. Bank of America boosted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday. Morgan Stanley lifted their price objective on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Saturday, September 27th. UBS Group reaffirmed a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Finally, Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $28.41.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.